| :: cardiome pharma |
Dr. Boivin is Cardiome's Vice President of Pharmaceutical Sciences & Manufacturing. Dr. Boivin has over 18 years of Pharmaceutical
Cardiome Pharma (NASDAQ:CRME) traded in a range yesterday that spanned from a low of $3.09 to a high of $3.23. Yesterday, the shares fell
Search CARDIOME PHARMA CORP Company information, Financial News related to stock market and company performance.
Versant Partners and Dundee Securities have lowered their price targets on Cardiome Pharma (TSX:COM; NASDAQ:CRME) after it and
Renewable Energy Focus: international renewable energy news, features, events and jobs including solar, wind, biofuels, marine, tidal, geothermal and other
Canadian drug company Cardiome Pharma Corp said it was transferring the marketing rights for the intravenous version of its heart drug to
Cardiome Pharma Corp. stock price today: (CRME) stock quote, price history, earnings per share, technical analysis chart and breaking news.
EV / EBITDA Use Average, CRME CARDIOME PHARMA CORP, DNA Genentech , Inc. Change, AMGN Amgen, Inc. Change, CELG Celgene Corporation
Cardiome Pharma Corp. topped the list of Biggest Percentage Price Gainers among common stocks on the Nasdaq Stock Market. See the full
View Cardiome Pharma Cp CRME investment & stock information. Get the latest Cardiome Pharma Cp CRME detailed stock quotes, stock data, Real-Time ECN,
Cardiome Pharma Corp. (formerly Nortran Pharmaceuticals Inc.) is a drug discovery and development company focused on developing proprietary drugs to treat
Cardiome Pharma Corp - 6-K - For 4/1/10 - Filing Submission - Report of a Foreign Private Issuer - Seq. 0 - Accession Number
Cardiome Pharma Corporation financial and business news, updates, and information from The New York Times and other leading providers.
Cardiome Pharma EPS of $(0.12) vs. $(0.11) Estimate; Revenues $0.4M vs. $1.06M Estimate. By Benzinga Staff May 16, 2011 3:11 PM. Symbols: CRME
VANCOUVER - Drug developer Cardiome Pharma Corp. (TSX:COM) reported a net loss in the latest quarter as the company's revenues fell
Cardiome Pharma (NASDAQ: CRME) picked a bad day for good news. According to the AP the company announced "interim midstage data
Cardiome Pharma Corp. (Formerly Nortran Pharmaceuticals Inc.) 6190 Agronomy Road, 6th Floor Vancouver British Columbia V6T 1Z3 Canada
US:CRME - Get Stock quote detail for Cardiome Pharma Corp. Stock quotes include the latest US:CRME market price and fundamental investing data, price.
Cardiome Pharma Corp.'s licensing agreement with Merck & Co. Inc, the largest of its kind in Canadian history, got the company on solid
VANCOUVER, March 9 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. ( NASDAQ: CRME) (TSX: COM) today announced that it will report financial results for
[CDATA[CARDIOME PHARMA CORP: Earnings worse than the estimates]]>. 69 days [CDATA[Biotech Stock in Focus; Cardiome Pharma Review]]>. 168 days
Free stock quote for . Stock price, charts, stock information, technical opinions.
17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced today that it is offering 8000000 common
Stock analysis for COM:CN. Get stock price, historical stock charts & news for Cardiome Pharma Corp, in the Medical-Drugs industry.
Shares of Cardiome Pharmaceuticals (CRME) are down after the company said its development of a key drug to treat irregular heartbeats will
Merck & Co., Inc. and Cardiome Pharma Corp. announced a collaboration and license agreement that provides Merck with exclusive global rights to the oral
Get the latest stock quote and more - DailyFinance is your source for Cardiome Pharma Corp. (USA) stock price. Interactive Data Managed
Cardiome Pharma Corp (CRME) - Financial and Strategic SWOT Analysis Review Summary Cardiome Pharma Corp. (Cardiome) is a drug
Get detailed financial information on CARDIOME PHARMA CORP (NASDAQ: CRME) including real-time stock quotes, historical charts & financial news, all for
Cardiome Pharma Corp. is a product-focused drug development company Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock
Vancouver, Canada, January 23, 2007 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has closed its
CARDIOME PHARMA CORP a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases reported that its
Free Online Library: Nortran Changes Name To Cardiome Pharma Corp. by " Business Wire"; Business, international Securities industry Stock
Cardiome Pharma (NASDAQ: CRME) was upgraded by equities research analysts at Zacks Investment Research from an 'underperform' rating
Cardiome Pharma Corp (CRME) insider Adage Capital Partners Gp LLC sells $5148000 of stock.
SmarTrend has detected shares of Cardiome Pharma (NASDAQ:CRME) have bullishly opened above the pivot of $7.99 today and have
In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by
Operating Name: Cardiome Pharma Corp. Cardiome Pharma Corp. is a product-focused drug development company dedicated to the
Based in Vancouver, Cardiome Pharma Corp. is a drug development company dedicated to the commercialization of new treatments for
See the company profile for Cardiome Pharma Corporation (CRME) including business summary, industry/sector information, number of employees, business
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia
Recent 52-Week Low Surpassed in Shares of Cardiome Pharma (CRME) Real -time stock quotes for Cardiome Pharma Corp. include COM
Results 1 - 17 of 17 CARDIOME PHARMA CORP: CRME (Nasdaq Global Market) SC 13G/A, CARDIOME PHARMA CORP (FMR LLC), 02/14/11. SC 13G/A
Cardiome Pharma Corp. (Cardiome) is a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases. Cardiome has one
May last post on Cardiome Pharma Corp.( COM TSX) was on May 31, 2010 for Mario. At the time it looked like COM had gotten ahead of itself.
Given the selling momentum, a retest of the lows at $4.60 may be required before a recovery.
Cardiome Pharma Corp. insider trading by executives and
21 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. today announced that it has amended its Disclosure Policy to enable its directors, officers
Selftrade is an execution-only stockbroker offering online and telephone services , flat £12.50 for all online trades, dealing and tax-efficient accounts, UK and
Paralex Inc., with intellectual property rights licensed from John Hopkins University, is developing a xanthine oxidase inhibitor that is targeted at
Today Penny Payday brings you a video chart for Cardiome Pharma Corp. ( CRME), a NASDAQ company and one of many you can find at
CARDIOME PHARMA CRME stock price, will CRME stock price go up? Is it a good time to buy CRME stock. Buy or sell CARDIOME PHARMA stock?
CARDIOME PHARMA CORP (CRME:US) stock price & investing information. Find CARDIOME PHARMA CORP historical stock quotes, key competitors, stock
Cardiome Pharma Corp. (CRME) announced that they received an approval related to an intravenous formulation of their Brinavess brand
CONFIDENTIAL - CARDIOME PHARMA. CORP. & NX PHARMAGEN, INC. Cardiome Pharma Corp. is solely represented as the sponsor of this presentation
Do not invest in Cardiome Pharma Cp (CRME) stock before you read this free research report on the company.
View the latest CRME - Cardiome Pharma real-time stock quote information. Get detailed breaking investment performances, chart analysis, stock prices,
Cardiome Pharma Corp (CRME), Financial and Strategic SWOT Analysis Review : , published August 2011, pages 37, Cardiome Pharma Corp (CRME)
Motley Fool. Wed, 07/27/11 - 9:54 pm. tags: Astellas, Bristol-Myers Squibb, Cardiome, JNJ, Merck, Pfizer · Cardiome Pharma 3Q profit surges on Merck payment
In-depth Company Financials with Key Ratios, and Revenue details by segments and geographies for the last five years download the attached
CRME - Cardiome Pharma Corporation stock information, company history, stock price history, stock quote, stock market news, recent news, recent headlines for
A positive endorsement from Merck & Co. for Cardiome Pharma Corp.'s heart drug, vernakalant, sent shares of Vancouver-based company up nearly 30% on
VANCOUVER, CANADA, July 28, 2009 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has earned a US$15 million milestone
Get the detailed quarterly/annual income statement for Cardiome Pharma Corporation (CRME). Find out the revenue, expenses and profit or loss over the last
Further study details as provided by Cardiome Pharma: Primary Outcome Measures: To demonstrate the effectiveness of RSD1235 in the
Update on November 3, 2011: Cardiome Pharma Corp., a Canada-based cardiovascular drug development company, has announced its
Up to date analysis of Cardiome Pharma Corporation (CRME) and its stock by hedge fund managers and industry experts. Find out what
Cardiome Pharma Corporation (CRME) rated Outperform with price target $6 by RBC Capital Mkts - GainersToday. See more Stock market
Jeff Rands, Major Account Manager, Canada of VWR International presents Doug Janzen of Cardiome Pharma Corp. with the award for COMPANY OF THE
TORONTO, Aug 8 (Reuters) - Cardiome Pharma Corp on Monday reported a quarterly net loss as revenue tumbled and research and development costs rose.
Company profile for Cardiome Pharma. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by therapy
Cardiome's detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry
Oxipurinol is currently being developed by Cardiome Pharma. It is waiting for approval in the US for the treatment of allopurinol-intolerant hyperuricaemia (gout )
Company: Cardiome Pharma Corp. Symbol: TSX: COM Nasdaq Canada: CRME. Address: 6190 Agronomy Road, 6th Floor Vancouver, British Columbia
From millions of real job salary data. 1 Cardiome Pharma Cardiovascular Research Scientist salary data. Average Cardiome Pharma Cardiovascular Research
VANCOUVER, British Columbia, Nov. 3, 2011 -- Cardiome Pharma Corp. is pleased to announce that its partner, Merck, has recently
News on Cardiome Pharma (Ticker: CRME) continually updated from thousands of sources around the net.
SmarTrend identified a Downtrend for Cardiome Pharma (NASDAQ: CRME) on June 03, 2011 at $4.71. In approximately 2 months since that
DUBLIN, Sep 10, 2010 (BUSINESS WIRE) -- Research and Markets
Cardiome Pharma Corporation is traded at NasdaqGM. Cardiome Pharma Corporation is a part of the Drug Manufacturers - Other industry, inside the Healthcare
Doug Janzen, CEO of Cardiome Pharma accepts the BIOTECanada Award for 2011 Company of the Year. Most Commented Posts: A look at
Cardiome Pharma (CRME), a Vancouver based developer of drugs to treat and prevent cardiovascular disease, is down 27 cents, or 6.75
Jobs At Cardiome Pharma Corp And Job Vacancy In Cardiome Pharma Corp . Cardiome Pharma Corp Jobs Directly.
Cardiome Pharma Corporation stock price & investing information, analysis, key competitors, stock data, executives and latest news.
Below is a list of the companies that made news in the healthcar.
Cardiome Pharma Corp. (British Columbia, Vancouver)
Cardiome Pharma (CRME, news, chart, volatility) options flow today is 13x normal for the name and appears to indicate a customer buying
Dec 15, 2011 (SmarTrend(R) News Watch via COMTEX) -- Cardiome Pharma ( NASDAQ:CRME) traded in a range yesterday that spanned from a low of $1.86 to
Id. vLex: VLEX-208588107 - CARDIOME PHARMA GETS TENER OFFER TO BUY US$27.5 MIL OF COMMON SHARES. - Biotech Financial Reports - Nbr. 1610
Facts and figures about Cardiome Pharma Corporation, taken from Freebase, the world's database.
Cardiome Pharma (NASDAQ: CRME) was downgraded by equities research analysts at Zacks Investment Research from a “neutral” rating to
Cardiome Pharma. COM; TSX; Consumer Products. Latest 2.53; CurrencyC$; Change -0.05; Percent Change -1.94%; Volume 13210; Jan 11, 2012 3:59:56 PM
Cardiome Pharma was a leading decliner within the health care sector, falling 10 cents (-2.9%) to $3.32 on average volume..
Wedbush Securities downgraded its rating on shares of Cardiome Pharma Corp. (NASDAQ: CRME) to “neutral” from “outperform” as the trial of
Cardiome Pharma Corporation Message board - Online Community of active, educated investors researching and discussing Cardiome Pharma Corporation
Results 1 - 20 of 240 CARDIOME PHARMA CORP: CRME (Nasdaq Global Market) 6-K, CARDIOME PHARMA CORP, 11/04/11 (11/04/11). 6-K, CARDIOME
Results 1 - 10 Everything you need to know about Senior Director Of Research Chemistry At Cardiome Pharma Corp - Professional Experience,Email,Phone
Cardiome Pharma Corp. Announces US$25 Million Advance on Line of Credit.
Home | Login | Stockstream. Cardiome Pharma Corp. com go to snapshot add to favorites. post. see all posts, Overall Quality 2+, Overall Quality
Cardiome Pharma Corp. Amended 2001 Incentive Stock Option Plan - This Option Agreement Involves Cardiome Pharma Corp.
Nov 10, 2011 / 12:00AM, Earnings, Sep 2011 Cardiome Pharma Earnings Nov 11, 2010 / 4:15PM, Conference Call, Cardiome Pharma
Cardiome Pharma Corp (Nasdaq:CRME) has been upgraded by TheStreet Ratings from a sell to hold..
Company Profile for Cardiome Pharma's Company Profile, News and Jobs - Cadiome Pharma Corp is pharmaceutical research and
VANCOUVER - Drug developer Cardiome Pharma Corp. (TSX:COM) reported a net los.
Find Cardiome Pharma Corp and other Physicians & Surgeons. Maps, directions, reviews, and contact information at Canpages.ca.
Vancouver, Canada, August 8, 2011 — Cardiome Pharma Corp. today reported financial results for the second quarter ended June 30, 2011.
Cardiome Pharma Corp. Company & Business Contact information- Jigsaw Business Directory. Get complete contact & company information with emails and
Cardiome Pharmaceutical Stock Message Board, CRME Stock Quote, CRME Stock Chart, CRME Stock News.
Cardiome Pharma is a product based drug development company for the treatment of cardiovascular diseases. The company has two clinical
Cardiome Pharma Corp (NASDAQ:CRME). Real-Time Quotes. Add to Watch List CRME News | Press Releases. No recent news for Cardiome Pharma Corp.
Cardiome Pharma has terminated its agreement with Astellas Pharma US, Inc. and transferred rights for the development and
Cardiome Pharma Corp (formerly Nortran Pharmaceuticals) - a Vancouver-based drug discovery and development company - has an interest in cardiac disease
Stock quote for Cardiome Pharma Corporation (CRME) - Get real-time last sale and extended hours stock prices, company news, charts, and
Hoovers company profile of Cardiome Pharma Corp.. Find detailed business information such as key executives, financials and other corporate data on
Merck, known as MSD outside the U.S. and Canada, and Astellas US, the U.S. subsidiary of Astellas Pharma, have entered into an agreement under which
Financial News - Cardiome Pharma Corp (CRME.O) - Cardiome Reports Third Quarter Results.
Cardiome Pharma' s 3rd-quarter profit surges on payment from heart drug partner Merck.
CRME, CARDIOME PHARMA CORP, 8.00, +1.76, +28.2%, 5.6k, 12.62, 5.78. VDSI, VASCO DATA SEC INTL INC, 11.80, +0.14, +1.2%, 4.2k
SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.
Find financial news for CARDIOME PHARMA CORP (NASDAQ:CRME) using Google Finance.
Let it break above $9 first and establish support at $8.
21 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. today announced that it has amended its Disclosure Policy to enable its directors, officers
Cardiome Pharma Corp. (NASDAQ: CRME), a Vancouver, Canada-based life sciences company focusing on the development of drugs to treat
Cardiome Pharma Names Bob Rieder New Chairman.
Description of the stock CRME, Cardiome Pharma Corp, from ETF Channel.
Merck & Co gets rights to Cardiome's vernakalant, for as much as $600 million. merck, co, gets, rights, cardiome, vernakalant, much.
Cardiome Pharma Corp. Research Associate, Pharmacology Cardiome Pharma Corp. Manager, CMC Quality Assurance Cardiome Pharma Corp. November 14
CARDIOME PHARMA CORP (NASDAQ:CRME). Last Market Price: 4.45, Change : +0.07, % Change: (1.60%). Shares trade in the range of 4.42
Summarized and detailed insider trading data for Cardiome Pharma Corp ( CRME).
Cardiome Pharma Corp (CRME) Cardiome Pharma Corp (CRME). Profile; Hedge Fund Holdings · Insider Purchases · Insider Sales
Cardiome Pharma Corp (CRME). Drugs are bad. Just say no to drugs. Unless they're legal and they're going to help you overcome pain or some other disease.
Cardiome Pharma is involved in the development and
The National Post reports in its Thursday, April 9, edition that Cardiome Pharma has executed a deal with drug giant Merck & Co. that could be
News after the close today on Cardiome Pharma Corp. (CRME) - the stock was halted briefly today but opened at $7.00 in afterhours.
Enter your e-mail address: Tweet. Freebase CC-BY. Source: Cardiome Pharma Corporation on Freebase licensed under CC-BY. show all images(). hide
Cardiome - Research Scientist, Synthetic Chemistry (Expired). Cardiome Pharma Corp. CANADA. Position Summary The incumbent is
Summary Free Membership Add to watchlist Email to friendSee.
Vancouver's Cardiome Pharma Corp. (TSX:COM; Nasdaq:CRME) has far from reaped all the potential rewards from the $913.6 million
Roberto Mignone's hedge fund, Bridger Management, disclosed a 5.5% ownership in Cardiome Pharma Corp. (Nasdaq:CRME), or owner of
Status, Indication, Name(s), Phase, Trial Name, Identification. Completed, Atrial Flutter, >Vernakalant Injection 20 mg/mL, Phase_II Phase_III, A Phase II/III
In a 13G filing with the SEC, hedge fund Bridger Management has disclosed a 5.1% ownership stake in Cardiome Pharma Corp (CRME).
For more ratings news on Cardiome Pharma click here and for the rating Shares of Cardiome Pharma closed at $5.42 yesterday, with a 52
Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) is pleased to announce that its partner, Merck, has recently completed an additional
About Cardiome Pharma Corp., Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs
Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for
EV/EBITDA ratio of Cardiome Pharma Corp. (CA14159U2020 - COM) and its peer group for financial analysis.
Cardiome Pharma Corporation (CRME) Competitors - View direct and indirect business competitors for Cardiome Pharma Corporation and all the companies
Cardiome Pharma's (CRME) recent gap higher has captured the attention of options traders and analysts.
Cardiome Pharma's press release, blog etc · Cardiome Reports Second Quarter Results · Cardiome Consents to Transfer of North American Rights for
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial
Latest Cardiome Pharma Corp. Share Price and News. Cardiome Pharma is a life sciences company focused on developing drugs to treat or prevent
Cardiome Pharma Corp Financial and Strategic Analysis Review Cardiome Pharma Corp. (Cardiome) is a drug research and development company that
Trial of Cardiome heart drug stopped after patient had a dangerous side effect. Cardiome Pharma 3Q Profit Surges On Merck Payment Tags: AP, ap us earns
1, 2005 (Canada NewsWire via COMTEX) -- Cardiome Pharma Corp. COMMUNICATIONS LTD RDATE:09042009 Cardiome Pharma Corp.
Cardiome Pharma Corp. (CRME, COM.TO) posted a third-quarter net loss of $7.2 million or $0.12 per share, compared to a net income of $22.8
CARDIOME - inspiring science. Login In collaboration with Merck, the intravenous formulation of Cardiome's lead Copyright 2012 Cardiome Pharma Corp.
Companies included in today's scan are: Northwest Bancorp (NWSB), Cardiome Pharma Corp (CRME), Texas Capital Bancshares (TCBI),
Cardiome Pharma Falls 1.96% on Heavy Volume: Watch For Potential Watch for Continued Losses in Shares of Cardiome Pharma (CRME)
InsideStocks is the leading provider of intraday stock and commodities realtime or delayed charts with powerful indicators and technical analysis. Search for
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies.
Cardiome Pharma Corporation (CRME) rated Outperform with price target $15 by Oppenheimer - GainersToday. See more Stock market
Cardiome Pharma Corp. Cardiome Reports Second Quarter Results Aug 08, 2011 Cardiome Reports 2010 Results Mar 10, 2011. from PR
Renewable Energy Financial News, Stocks, Companies, and Market Research.
View iStockAnalyst's scorecard for Cardiome Pharma Corporation(CRME). Learn more about investing into CRME from the industry experts. Track CRME
Cardiome Pharma Corp. (USA) (NASDAQ:CRME). + Watch CRME. on My Watchlist. $2.62 -0.03 (-1.13%). 1/5/2012 3:59 PM
The organizational chart of Cardiome Pharma displays its 15 main executives including Douglas Janzen, Curtis Sikorsky and Charles Fisher.
CARDIOME PHARMA CORP. - write and read reviews and find brand information for products and services associated with the CARDIOME PHARMA CORP.
Latest news for global professionals & analysts. Breaking news.
CARDIOME PHARMA CORP. is a drug development company focused on developing proprietary drugs to treat.
Cardiome Pharma Corp. (Nasdaq) led advancing issues, surging 84 cents, or 27 % on the week, to $3.97. Merck & Co. said it licensed an
CARDIOME PHARMA XETRA: CKO.DE,ETR:CKO technical analysis and research for investors, will it rise or fall?, come and read updated
Cardiome Pharma Corp. Is A Company. View Cardiome Pharma Corp. Company Information, Employment Statistics, Personnel Contacts, And Financial Report.
Canadian Stock Forums: Cardiome Pharma Corp, Rockcliff Resources Inc, Bioscrypt Inc, Redhawk Resources Inc., (TSX) COM:CA - Cardiome Pharma Corp
Zacks Investment Research downgraded shares of CARDIOME PHARMA ( CRME) from NEUTRAL to UNDERPERFORM on September 27,
Cardiome Pharma and Astellas Pharma U.S. Announce PDUFA Action Date Extended by Three Months VANCOUVER, and DEERFIELD, IL,
Cardiome Pharma Corp. (Nasdaq: CRME) reported positive results from a midstage clinical trial of its abnormal heart rhythm treatment
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia
Merck, known as MSD outside the US and Canada, and Cardiome Pharma have received recommendation for the marketing approval of
NASDAQ: CRMETSX: COMVANCOUVER, May 28 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. today announced positive interim clinical
Cardiome Pharma Corp. Announces New Expiration Date For Tender Offer. 25 September. Cardiome Announces Next Steps for GED-aPC Asset and Transition
Cardiome Pharma Corp. is a life sciences company which is focused on developing drugs to treat or prevent cardiovascular diseases.
Cardiome Pharma Corp. is a research and development company which is principally engaged in the development of drugs to with focus on cardiovascular d.
Cardiome Pharma Corp. is a product-focused drug development company dedicated to For more information, please visit our web site at www.cardiome. com.
China GPS Alarm Center supplier - Cardiome Pharma Corp. Co.,Ltd is quality Auto rearview mirror 3G Camera for Car GPS Positioning manufacturer providing
CARDIOME - inspiring science. Login. Search this site: Contact Copyright 2012
CRME - Cardiome Pharma (CRME) Stock Research Analysis - Cardiome Pharma (CRME) Stock Research Analysis, Stock News, Stock Profile, Stock Summary,
Mr. Robert W. Rieder, M.B.A., is Chairman of the Board of Cardiome Pharma Corp. He is the Chairman of the Corporation, served as Chief Executive Officer from
Medical Officer and Executive Vice President of Cardiome Pharma Corp. where he led the team that invented, developed, registered and sold
Cardiome Pharma ([[ CRME ]] -7%) gets hit after Wedbush cuts the shares to Neutral, citing concern over continued delays in the Phase 3 trials for oral
Insider trades (SEC Form 4) for Cardiome Pharma Corporation (CRME). Displays all buying and selling activity for company insiders.
VANCOUVER, Oct. 21 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma
Global Markets Direct's Cardiome Pharma Corp - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of Cardiome
Shares of Cardiome Pharma Corp. (NASDAQ:CRME) rose 21% to $5.26 early Tuesday, ahead of a planned conference call with investors to
28 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today disclosed that its Chairman and Chief Executive Officer, Bob Rieder,
Company profile, information and contact info for Cardiome Pharma Corp. - 6190 Agronomy Rd., 6th Floor, Vancouver, BC from ProFile Canada, Canada's most
Cardiome Pharma Corp (Nasdaq:CRME) has been downgraded by TheStreet Ratings from from a hold to sell..
Get company information on Cardiome Pharma Corp. and millions of other companies using the OneSource Free Directory.
EvaluatePharma® is the premier online source for pharma and
Get the 411 on Cardiome Pharma Corp 6190 Agronomy Rd, Vancouver, BC, V6T 1Z3, it's fast and easy.
Cardiome Pharma Corp, Suite 6Fl-6190 Agronomy Rd., V6T 1Z3, Now listed on Canada's National Directory of Health Service Professionals.
Cardiome Pharma (NASDAQ: CRME) closed at $8.66 Monday. Phase 2b data is expected soon for a oral formulation of Kynapid (vernakalant),
Welcome to the company profile of Cardiome Pharma Corp on LinkedIn. Cardiome Pharma Corp. is a product-focused drug development company dedicated to
Cardiome Pharma Corp (CRME) - Financial and Strategic SWOT Analysis Review Cardiome Pharma Corp (CRME) - Financial and Strategic
Cardiome Pharma has announced that its co-development partner, Astellas Pharma, has suspended patient enrollment in the ACT 5 study of
NASDAQ: CRME TSX: COM VANCOUVER, Sept. 1 /PRNewswire-FirstCall/ - Cardiome Pharma Corp.
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with clinical drug programs. The Company's
Below is a list of the companies that made news in the healthcare sector on Wednesday, August 11, 2010. Cardiome Pharma Corp. (NASDAQ:
Bio tech name.Play with caution. Jan. 24 at 8:30PM · Cardiome Pharma Corp. $ CRME Stream_6kmdwif. Medium-1287022299 volpivots nice back-to-back days
View the basic CRME stock chart on Yahoo! Finance. Change the date range, chart type and compare Cardiome Pharma Corporation against other companies.
RBC Capital Markets upgraded its rating on shares of Cardiome Pharma Corp. ( NASDAQ: CRME) (TSX: COM) to " outperform" from "sector
Cardiome Pharma Aktie: Hier finden Sie den Cardiome Pharma Aktienkurs aktuell und ausserdem weitere Informationen wie den Cardiome Pharma Chart.
View CRME stock key valuation ratios, operation ratios, growth rates, trades of mutual fund and hedge fund managers, company executives and other insiders.
Cardiome Pharma Corp. company research & investing information. Find executives and the latest company news.
Cardiome Pharma (NASDAQ:CRME): RBC Capital Mkts reiterated its About the company: Cardiome Pharma Corp. is a product-focused
CRME Stock HQ. In-depth research & opinions on Cardiome Pharma Corp. ( CRME) from expert traders and investors who follow CRME closely.
Shares of Cardiome Pharma Corp. (NASDAQ:CRME) rose 21% to $5.26 early Tuesday, ahead of a planned conference call with investors to discuss the
HighBeam Research Article: CARDIOME PHARMA GETS TENER OFFER TO BUY US$27.5 MIL OF COMMON SHARES. By: . Published on
Acquisition Report on Cardiome Pharma: Advising on Acquisitions, Business Planning, Market Research, Corporate Investments: advising on syndicated
Company profile for Cardiome Pharma Corp. in Vancouver,BC. Get accurate business information including key contacts, company financials and more in the
Cardiome Pharma stock prices by StockNod. Current CRME stock price by day and historical Cardiome Pharma stock prices by month, quarter, and year for
Results 1 - 20 of 150 6-K, CARDIOME PHARMA CORP, 11/04/11 (11/04/11). 6-K, CARDIOME PHARMA CORP, 11/04/11 (11/03/11). 6-K, CARDIOME PHARMA
Browse by: INVENTOR · PATENT HOLDER · PATENT
VANCOUVER, May 16 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME) (TSX : COM) today reported financial results for the first quarter
Get real-time stock quote for Cardiome Pharma Corporation CRME including chart, current price, historical price, news, financial statements, balance sheet,
OF PATIENT ENROLMENT IN ACT 5 TRIAL. Vancouver, Canada and Deerfield, Illinois, USA, October 28, 2009 -- Cardiome Pharma Corp. (NASDAQ: CRME
Research and review Cardiome Pharma Corp. jobs. Learn more about a career with Cardiome Pharma Corp. including all recent jobs, hiring trends, salaries,
Cardiome Pharma Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report - new company profile.
Company Profile for including business summary, key statistics, ratios, sector.
Looking for Cardiome Pharma Jobs Canada? Visit Canada Jobs for Cardiome Pharma Jobs Canada, employment and career opportunities. Apply for a job
UPDATE 1-Cardiome reports loss as revenue drops Aug 08, 2011. TORONTO, Aug 8 (Reuters) - Cardiome Pharma Corp on Monday reported a quarterly net
11.11.2011 - Wedbush Securities downgraded its rating on shares of Cardiome Pharma Corp. (NASDAQ: CRME) to "neutral" from "outperform"
Cardiome Pharma Corp. (Cardiome) is a life sciences company focused on developing drugs to treat or prevent cardiovascular diseases.
COM, August 12, 2010 ) Dallas, Tx - Stock price of pharmaceutical company CARDIOME Pharma Corporation (NASDAQ: CRME) was down by
Merck and Cardiome Pharma Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation; Cardiome to
Cardiome Pharma Corp. 600-6190 Agronomy Rd Vancouver, BC V6T 1Z3 Tel: ( 604) 677-6905. Toll-free: (800) 330-9928. Fax: (604) 677-6915. Contact Name
Nice pop the other day, once it fills the gap might be worth a play.
Q4 2010 Earnings Call - Cardiome Pharma Corp., - Earnings Transcript Thursday , March 10, 2011 09:30.
PGE Pfizer, COM Cardiome Pharma. January 31st, 2011. PFE 2011 big. It took ten years to go from $3 to $50. Then it took ten years to lose 76% (a Fibo#) of that .
Global Market Direct's pharmaceuticals report, "Cardiome Pharma Corp - Product Pipeline Review - Q4 2010" provides data on the company's
Cardiome Pharma Corp. operates in the Pharmaceutical preparations sector. Cardiome Pharma Corp. (Cardiome) is a life sciences company focused on
Cardiome Pharma Corp. is a product-focused cardiovascular drug development company. Cardiome has three late stage clinical drug programs focused on
VANCOUVER, March 15 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME) ( TSX: COM) announced today that Doug Janzen, President and
Cardiome Pharma Corporation (CRME) stock quote, charts, historical data, financials.
Directory of patents owned by Cardiome Pharma (121 patents):
Institutional investors held total 43140594 shares of
Results 1 - 10 of 119 Directory of patents owned by Cardiome Pharma (119
Cardiome Pharma Corp. Doug Chou, Research Scientist - Medicinal Chemistry; Peter Orth, Head of Biology Frederica Bell, Corporate Communications
Cardiome Pharma Corp. is a life sciences company which is focused on developing Cardiome Pharma: New 52-Week Low Set Today (CRME) Nov 15, 2011
Cardiome Pharma Corporation. Cardiome Pharma Corp. is a life sciences company which is focused on developing drugs to treat or prevent cardiovascular
Alle News zu CARDIOME PHARMA Aktien. Highest Enterprise Value to Sales Ratio in the Pharmaceuticals Industry Detected in Shares of Cardiome Pharma.
Cardiome Pharma (Nasdaq: CRME) 13.3% HIGHER; after testing and. Cardiome Pharma Corporation (CRME) Reports Q2 Loss of $0.13, Revenues Fell 97%
Message Boards Settings Cardiome Pharma Corp. Search : in. Cardiome Pharma Corp. board, Stocks C category, Stocks (A to Z) category, All Yahoo! Message
Financial News - Cardiome Pharma Corp (CRME.O) - Cardiome Pharma Corp. Announces Preliminary Results of Tender Offer.
Cardiome Pharma (CRME) Video Stock Chart 11/11/2010, The stock chart for Cardiome Pharma (CRME) is in a pincher play bottom formation
Cardiome Pharma Corporation Vancouver reviews by real people. Yelp is a fun and easy way to find, recommend and talk about what's great and not so great in
Guy Cipriani Cardiome Pharma Corp. VicePresidant - Buisness Development - Profile From Walker's Research.
Cardiome Pharma announces sale of Anti-Tussive program to UCB, S.A..
Cardiome Pharma Corp. (CRME) shares were up more than 30% after the company announced positive interim clinical results from its 90-day
Cardiome Pharma news and press releases about recent investments, fund and portfolio company news, new hires and events.
Cardiome Pharma (CRME). @ 4:00 PM 4, 2011 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today reported more .
Cardiome Pharma. Corp. Employer - Salary - Get a free salary comparison based on job title, skills, experience and education. Accurate
2011-12-31 CRME: Cardiome Pharma Corp Institutional Investments! Cardiome Pharma Corp bought a new position of 424143 shares, change of 100% to total
CARDIOME PHARMA CORP (CRME). Nasdaq: CRME; Mkt.Cap.:135.71M. Sector Pure-Play: Healthcare > Biopharmaceuticals > Cardiovascular System
Cardiome Pharma Cut To Neutral From Outperform By Wedbush >CRME. Subscriber Cardiome Pharma Started At Outperform By BMO >CRME. Subscriber
A product-focused cardiovascular drug development company based Vancouver. (Nasdaq: CRME)
Cardiome Pharma Corporation (CRME) Reports Q2 Loss of $0.13, Revenues Fell 97% Y/Y. Graphic_arrow1 Cardiome Reports Second Quarter Results
Artesian Therapeutics, Inc. (now part of Cardiome Pharma Corp.) About Us Artesian Therapeutics, Inc is a privately-held biopharmaceutical company founded to
CARDIOME PHARMA CORP Provides Update For Oral Vernakalant CARDIOME PHARMA CORP announced that it has been advised by its partner, Merck
Operator: Good morning ladies and gentlemen, and welcome to the Cardiome Third Quarter 2011 Financial Results Conference Call. Please
CARDIOME PHARMA CORP ( NASDAQ:CRME ) . Last Market Price: 2.87, Change: -0.25, % Change: (-8.01%). Shares trade in the range of
Cardiome Pharma Corporation (CRME) Reports Q2 Loss of $0.13, Cardiome Pharma Corporation (NASDAQ: CRME) reported Q2 EPS of
Name: